PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway

Molecular and Cellular Biochemistry

Volumn 300, Issue 1-2, 2007, Pages 77-87

  Koul, Dimpy ^a   Shen, Ruijun ^a   Shishodia, Shishir ^a   Takada, Yasanuri ^a   Bhat, Krishna P ^a   Reddy, Shrikanth A G ^a   Aggarwal, Bharat B ^a   Yung, W K Alfred ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AP 1; c fos; PI3kinase; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE INDUCTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MUTANT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GLIOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-FOS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249977094     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-9371-8     Document Type: Article

References (44)

1. Walker MD, Alexander E, Hunt WE (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 49:333-343
2. Walker MD, Green SB, Byar DP (1980) TNF and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. N Engl J Med 303:1323-1329
3. Davis FG, McCarthy BJ, Freels S (1999) The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology, and end results (SEER) data. Cancer 85:485-491
4. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci USA 96:4240-4245
5. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39
6. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK (1998) The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 95:13513-13518
7. Vazquez F, Sellers WR (2000) The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470:M21-M35
8. Leevers SJ, Vanhaesebroeck B, Waterfield MD (1999) Signaling through phosphoinositide 3-kinases: The lipids take centre stage. Curr Opin Cell Biol 11:219-225
9. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241
10. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1997) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321
11. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868
12. Romashkova JA, Makarov SS (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signaling. Nature 401:86-89
13. Reddy SAG, Huang JH, Liao L (2000) Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kappa B activation. J Immunol 164:1355-1363
14. Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA (2001) Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem 276:11402-11408
15. Karin M, Liu Z, Zandi E (1997) AP-1 function and regulation. Curr Opin Cell Biol 9:240-246
16. Curran T, Franza BR Jr (1988) Fos and Jun: The AP-1 connection. Cell 55:395-397
17. Eferl R, Wagner EF (2003) AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 3:859-868
18. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, Spiegelman BM (1995) c-fos is required for malignant progression of skin tumors. Cell 82:721-732
19. Malliri AM, Symons RF, Hennigan AF, Hurlstone RF, Lamb T, Wheeler BW (1998) The transcription factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. J Cell Biol 143:1087-1099
20. Belguise KN, Kersual F, Galtier D (2005) FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24:1434-1444
21. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18:7095-7105
22. Angel P, Karin M (1991) The role of Jun, Fos, the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129-157
23. Jochum W, Passegué E, Wagner EF (2001) AP-1 in mouse development and tumorigenesis. Oncogene 20:2401-2412
24. Shaulian E, Karin M (2001) AP-1 in cell proliferation and survival. Oncogene 20:2390-2400
25. Huang C, Schmid PC, Ma WY, Schmid HH, Dong Z (1997) Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J Biol Chem 272:4187-4194
26. Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK (2002) Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 15:2357-2364
27. Reddy SAG, Huang JH, Liao WSL (1997) Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation. J Biol Chem 272:29167-29172
28. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102
29. Gopalan SM, Wilczynska KM, Konik BS, Bryan L, Kordula T (2006) Astrocyte-specific expression of the alpha1-antichymotrypsin and glial fibrillary acidic protein genes requires activator protein-1. J Biol Chem 281:1956-1963
30. Sizemore N, Leung S, Stark GR (1999) Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19:4798-4805
31. Huang C, Ma WY, Dong Z (1996) Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol Cell Biol 16:6427-6435
32. Van Leeuwen JE, Paik PK, Samelson LE (1999) Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol 3-kinase association. J Biol Chem 274:5153-5162
33. Fahy BN, Schlieman M, Virudachalam S, Bold RJ (2003) AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89:391-397
34. Shah SA, Potter MW, Hedeshian MH, Kim RD, Chari RS, Callery MP (2001) PI-3′ kinase and NF kappaB cross-signaling in human pancreatic cancer cells. J Gastrointest Surg 5:603-612
35. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT (1995) Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268:100-102
36. Barber JR, Verma IM (1987) Modification of fos proteins: Phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. Mol Cell Biol 7:2201-2211
37. Holt JT, Gopal TV, Moulton AD, Nienhuis AW (1986) Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. Proc Natl Acad Sci USA 83:4794-4798
38. Piechaczyk M, Blanchard JM (1994) c-fos proto-oncogene regulation and function. Crit Rev Oncol Hematol 17:93-131
39. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ (1995) Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221:706-718
40. Arteaga CL, Holt JT (1996) Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res 56:1098-1103
41. Gee JM, Ellis IO, Robertson JF, Willsher P, McClelland RA, Hewitt KN, Blamey RW, Nicholson RI (1995) Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 22:269-273
42. Preston GA, Lyon TT, Yin Y, Lang JE, Solomon G, Annab L, Srinivasan DG, Alcorta DA, Barrett JC (1996) Induction of apoptosis by c-Fos protein. Mol Cell Biol 16:211-218
43. Gajate C, Alonso MT, Schimmang T, Mollinedo F (1996) C-Fos is not essential for apoptosis. Biochem Biophys Res Commun 21:267-272
44. Roffler-Tarlov S, Brown JJ, Tarlov E, Stolarov J, Chapman DL, Alexiou M, Papaioannou VE (1996) Programmed cell death in the absence of c-Fos and c-Jun. Development 122:1-9